RC
NMRA icon

RBF Capital’s Neumora Therapeutics NMRA Stock Holding History

RBF Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Hold
90,000
– – 0.01% 489
2026
Q1 		$176K Sell
90,000
-15,174
-14% -$39.3K 0.01% 464
2025
Q4 		$188K Sell
105,174
-34,826
-25% -$76.3K 0.01% 521
2025
Q3 		$255K Sell
140,000
-20,000
-13% -$32.3K 0.01% 497
2025
Q2 		$117K Buy
+160,000
New +$121K 0.01% 565

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

RBF Capital's NMRA Position: Q2 2026 in Review

RBF Capital held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 90,000 shares worth $153K. The position accounts for 0.01% of the portfolio, ranked #489.

RBF Capital first reported a position in NMRA in Q2 2025 and has held it in 5 quarters since. The position peaked at $255K in Q3 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • RBF Capital held 90,000 shares of Neumora Therapeutics worth $153K as of Q2 2026.
  • RBF Capital left its Neumora Therapeutics share count unchanged in Q2 2026.
  • Neumora Therapeutics made up 0.01% of RBF Capital's portfolio in Q2 2026, its #489 holding.
  • RBF Capital first reported a position in Neumora Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • RBF Capital's Neumora Therapeutics position peaked at $255K in Q3 2025.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.